See more : Exel Composites Oyj (EXL1V.HE) Income Statement Analysis – Financial Results
Complete financial analysis of HOOKIPA Pharma Inc. (HOOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOOKIPA Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Energi Mega Persada Tbk (ENRG.JK) Income Statement Analysis – Financial Results
- Sensec Holding AB (publ) (SECS.ST) Income Statement Analysis – Financial Results
- CNNC Hua Yuan Titanium Dioxide Co., Ltd (002145.SZ) Income Statement Analysis – Financial Results
- Pantech Group Holdings Berhad (5125.KL) Income Statement Analysis – Financial Results
- MariMed Inc. (MRMD) Income Statement Analysis – Financial Results
HOOKIPA Pharma Inc. (HOOK)
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.13M | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 3.55M | 3.60M | 4.64M | 53.13M | 46.31M | 21.97M | 398.00K |
| Gross Profit | 16.58M | 10.65M | 13.81M | -33.55M | -34.37M | -14.34M | -398.00K |
| Gross Profit Ratio | 82.35% | 74.72% | 74.85% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 86.42M | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | -392.00K | -2.84M | 3.07M | 601.00K | 133.00K | -25.00K |
| Operating Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Cost & Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Interest Income | 5.29M | 8.24M | 27.00K | 9.20M | 1.59M | 0.00 | 0.00 |
| Interest Expense | 317.00K | 687.00K | 898.00K | 786.00K | 877.00K | 778.00K | 606.00K |
| Depreciation & Amortization | 3.55M | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -77.34M | -60.40M | -70.13M | -39.15M | -39.09M | -14.80M | -13.76M |
| EBITDA Ratio | -384.24% | -513.40% | -442.73% | -272.08% | -427.78% | -193.93% | 0.00% |
| Operating Income | -97.69M | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -485.34% | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 16.48M | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -81.21M | -64.92M | -75.67M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -403.46% | -455.58% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 368.00K | 230.00K | 1.00K | -10.28M | -8.89M | 24.00K | 4.00K |
| Net Income | -81.58M | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| EPS Diluted | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| Weighted Avg Shares Out | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for February 2nd
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
Source: https://incomestatements.info
Category: Stock Reports